News
A Significant Step Toward Greater Clarity in Polymorph Control for Innovative Drugs
28 Jan 2026
en
Crystal Pharmatech is heading to BioTechX USA 2025!
We're excited to join our partner biosimulytics at Booth S5 on September 16-17 in Philadelphia.
Come meet our Co-founder & CBO, Dr. Robert Wenslow, and Subject Matter Expert, Derik McCarthy, as we showcase how integrated in silico prediction + experimental CMC strategy can accelerate small molecule development.
With Peter F Doyle (CEO, Co-Founder & Board Member) and Johannes Eiglsperger (CTO) of Biosimulytics also attending, we'll dive into how:
AI-powered solid-state prediction enables smarter form selection
API-sparing workflows reduce IND risk by improving solubility and PK early
Collaborative platforms can de-risk formulation and accelerate decision-making
Attendee:
Robert Wenslow, Ph.D.
Co-founder and CBO
Crystal Pharmatech
Derik McCarthy
Subject Matter Expert
Crystal Pharmatech
Ready for an evening of unscripted connection?
Please complete the form to register for our San Diego Biotech and Pharma R&D social. Note: Registration is subject to review. You will receive a formal confirmation email once your attendance is approved.
By providing your e-mail address, you agree to receive an e-mail response from Crystal Pharmatech to your registration. The information you submit will be governed by our Privacy Policy.
_.webp "A Significant Step Toward Greater Clarity in Polymorph Control for Innovative Drugs")
Subscribe to be the first to get the updates!
